摘要
目的 :制备一种新的介入放射药物 1 86铼碘化油 ,并研究其安全性和肝癌组织中的定位程度。 方法 :通过理化方法将1 86铼包在医用碘化油中 ,制成 1 86铼碘化油 (1 86 Re- lipiodol,RL)。根据药典要求进行质量控制检验。选择原发性肝癌 (PL C)患者8例 ,经 Seldinger法插管到肝动脉 ,注入 RL 10～ 2 0 m l(内含 1 86铼 1110～ 2 2 2 0 MBq) ,通过动态 ECT扫描及感兴趣区 (ROI)测定 ,观察 RL 的生物学分布及对人体的毒性作用。 结果 :RL 完全符合药典标准 ,进入人体后对重要器官的毒性反应处于WHO标准的 0～ 2级间。注入的该制剂几乎全部分布于肝癌组织中 ,T/ NT值达 (10～ 14 ) / 1。结论 :成功地制备了一种新的具有良好安全性和肝脏特异分布的介入放射药物 1 86
Objective:To prepare and analyze the biodistribution of 186 Re lipiodol(RL) in patients with primary liver cancer(PLC), assessing the potential of RL as a radiopharmaceutical agent for the treatment of PLC.Methods:RL was synthesized from 186 Rhenium and lipiodol through physical and chemical procedure.Doses of RL ranged from 1 110 MBq to 2 220 MBq per patient depending on the size of tumors.Quantitative gamma camera imaging(ECT) and gamma counting of serum and urine were used to obtain data for dosimetry estimation.Results:In the hepatic tumor RL was selectively retained and radioactivity remained high throughout this study.The ratio of tumor concentration to the normal liver tissue concentration(T/NT ratio) was (10 14)/1 48 h after injection of RL.The main side effects of this therapy were transient fever and anorexia.No unacceptable toxicity was observed.Conclusion:The biodistribution and imaging results demonstrate that RL selectively localize in tumor, indicating RL may be a potential internal radiopharmaceutical agent for the treatment of primary liver cancer.
出处
《第二军医大学学报》
CAS
CSCD
北大核心
2003年第8期881-883,共3页
Academic Journal of Second Military Medical University
基金
国家"九五"重点科技攻关项目 ( 96-90 1-0 5 -182 )
